Attention subscribers
If you are a current subscriber but do not have an online account, click here to set up your free access.
Not yet a subscriber? click here to subscribe today.
Log in Subscribe

Legal questions swirl around FDA's new expedited drug program, including who should sign off

Posted 1/16/26

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been rocked by recent layoffs and resignations. Agency staffers and outside experts …

This item is available in full to subscribers.

Please log in to continue

Log in